This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Hemoglobin A1c Monitoring Industry

NEW YORK, Dec. 4, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Global Hemoglobin A1c Monitoring Industry

This report analyzes the worldwide markets for Hemoglobin A1c Monitoring in US$ Million. The report analyzes the Hemoglobin A1c Monitoring in Europe and Rest of World as a single consolidated segment, the US market is analyzed by the following Test Types: HbA1c Laboratory Testing, and HbA1c Point of Care Testing & Self-Monitoring. The report provides separate comprehensive analytics for US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 25 companies including many key and niche players such as Abbott Laboratories, Axis-Shield Plc, Bayer Healthcare Diabetes Care, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Diabetes Technologies Inc., Geonostics, Inc., HEMOCUE® AB, Menarini Diagnostics, Roche Diagnostics, Seradyn, Inc., Siemens Healthcare Diagnostics, Tosoh Bioscience, Inc., and Trinity Biotech plc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.


Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-2

Product Definition and Scope of Study I-3



HbA1c Testing on a Growth Spree II-1

Current and Future Analysis II-2

Home Monitoring - Laced with Accuracy Concerns II-2

Technology Developments Revolutionize Diagnostics in Diabetes

Care II-2

Higher Levels of Glycosylated Hemoglobin Increases the Risk of

Death II-3

Market Dynamics & Trends II-4

Regular HbA1c Test Keeps Heart Risk at Bay II-4

New Application to Boost Adoption II-4

Is HbA1c Test Right in Being Recommended for Diagnostic

1 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs